Tokyo Tape
Sign in
← Nihon Chouzai

Quarterly report · Q3

3341.TEDINET S100SVMG
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥254.1bn2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥313.3bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥232.8bn2022-04-01 → 2022-12-31Cons.Net sales
Operating income¥6.5bn2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥5.8bn2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income¥6.5bn2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥7.7bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥5.8bn2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥6.5bn2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥7.0bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥3.8bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.5bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥4.3bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥3.8bn2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥4.3bn2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥194.4bnat 2023-12-31Cons.Assets
Total assets¥185.3bnat 2023-03-31Cons.Assets
Total assets¥187.6bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥134.9bnat 2023-12-31Cons.Liabilities
Total liabilities¥128.8bnat 2023-03-31Cons.Liabilities
Net assets / equity¥59.5bnat 2023-12-31Cons.Net assets
Net assets / equity¥56.5bnat 2023-03-31Cons.Net assets
Net assets / equity¥56.3bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥16.9bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥23.8bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥125.992023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥67.552023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥148.922022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥143.232022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥89.642022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio30.6%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio30.5%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio30.0%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 37
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥10.0bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥10.0bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥5.4bn
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥225.6bn
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥225.6bn
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥10.6bn
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥7.4bn
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥7.3bn
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥35m
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥795m
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥31.2bn
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥21.2bn
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥9.9bn
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥555m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-12-31¥264.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-12-31¥254.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-12-31¥10.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-12-31¥12.0bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥10.5bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥10.5bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥4.9bn
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥208.1bn
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥208.1bn
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥2m
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥10.6bn
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥5.9bn
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥5.9bn
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥10m
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥602m
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥29.3bn
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥18.9bn
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥10.4bn
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2022-04-01 → 2022-12-31−¥456m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥243.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥232.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥10.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥10.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 356
ItemContextValueUnit
Liabilities and net assetsPrior1YearInstant185297000000JPY
Liabilities and net assetsCurrentQuarterInstant194365000000JPY
Net salesPrior1YTDDuration232844000000JPY
Net salesCurrentYTDDuration254127000000JPY
Cost of salesPrior1YTDDuration192233000000JPY
Cost of salesCurrentYTDDuration211315000000JPY
Gross profitPrior1YTDDuration40610000000JPY
Gross profitCurrentYTDDuration42812000000JPY
Selling general and administrative expensesPrior1YTDDuration34780000000JPY
Selling general and administrative expensesCurrentYTDDuration36262000000JPY
Operating incomePrior1YTDDuration5829000000JPY
Operating incomeCurrentYTDDuration6550000000JPY
Commission fee noiPrior1YTDDuration30000000JPY
Commission fee noiCurrentYTDDuration34000000JPY
Rent income noiPrior1YTDDuration438000000JPY
Rent income noiCurrentYTDDuration488000000JPY
Insurance income noiPrior1YTDDuration54000000JPY
Insurance income noiCurrentYTDDuration15000000JPY
Subsidy income noiPrior1YTDDuration26000000JPY
Subsidy income noiCurrentYTDDuration40000000JPY
Other noiPrior1YTDDuration203000000JPY
Other noiCurrentYTDDuration161000000JPY
Non operating incomePrior1YTDDuration753000000JPY
Non operating incomeCurrentYTDDuration739000000JPY
Interest expenses noePrior1YTDDuration201000000JPY
Interest expenses noeCurrentYTDDuration263000000JPY
Rent expense noePrior1YTDDuration330000000JPY
Rent expense noeCurrentYTDDuration323000000JPY
Other noePrior1YTDDuration214000000JPY
Other noeCurrentYTDDuration186000000JPY
Non operating expensesPrior1YTDDuration746000000JPY
Non operating expensesCurrentYTDDuration772000000JPY
Ordinary incomePrior1YTDDuration5836000000JPY
Ordinary incomeCurrentYTDDuration6517000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration1170000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration65000000JPY
Compensation income eiPrior1YTDDuration120000000JPY
Compensation income eiCurrentYTDDuration32000000JPY
Extraordinary incomePrior1YTDDuration1290000000JPY
Extraordinary incomeCurrentYTDDuration97000000JPY
Impairment loss elPrior1YTDDuration114000000JPY
Impairment loss elCurrentYTDDuration142000000JPY
Loss on sales of noncurrent assets elPrior1YTDDuration51000000JPY
Loss on sales of noncurrent assets elCurrentYTDDuration3000000JPY
Extraordinary lossPrior1YTDDuration166000000JPY
Extraordinary lossCurrentYTDDuration146000000JPY
Income before income taxesPrior1YTDDuration6960000000JPY
Income before income taxesCurrentYTDDuration6468000000JPY
Income taxes currentPrior1YTDDuration1720000000JPY
Income taxes currentCurrentYTDDuration1847000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass